Bristol/Sanofi Plavix Sales Triple In U.S.; Avapro Doubles
Executive Summary
Sanofi-Synthelabo is planning an aggressive clinical trial program to expand labeling for its pair of cardiovascular products co-promoted with Bristol-Myers Squibb in the U.S., Plavix and Avapro.
You may also be interested in...
Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins
Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.
Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins
Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.
Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program
Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.